CytomX Therapeutics (CTMX) Net Margin (2016 - 2025)
Historic Net Margin for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to 238.62%.
- CytomX Therapeutics' Net Margin fell 2557800.0% to 238.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 24.66%, marking a year-over-year increase of 137300.0%. This contributed to the annual value of 23.08% for FY2024, which is 236400.0% up from last year.
- Per CytomX Therapeutics' latest filing, its Net Margin stood at 238.62% for Q3 2025, which was down 2557800.0% from 0.83% recorded in Q2 2025.
- CytomX Therapeutics' 5-year Net Margin high stood at 49.55% for Q4 2024, and its period low was 353.77% during Q1 2022.
- Moreover, its 5-year median value for Net Margin was 26.02% (2024), whereas its average is 118.39%.
- In the last 5 years, CytomX Therapeutics' Net Margin crashed by -3203300bps in 2021 and then skyrocketed by 3396800bps in 2023.
- CytomX Therapeutics' Net Margin (Quarter) stood at 312.82% in 2021, then skyrocketed by 86bps to 43.61% in 2022, then skyrocketed by 107bps to 3.15% in 2023, then soared by 1475bps to 49.55% in 2024, then plummeted by -582bps to 238.62% in 2025.
- Its last three reported values are 238.62% in Q3 2025, 0.83% for Q2 2025, and 46.2% during Q1 2025.